PharmaDEXI
The computed 12-month bankruptcy probability of PharmaDEXI is 12.9% (high). The 2023 annual accounts show negative equity (€-40k) and a net result of €-15k. The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-40k |
| Net result | €-15k |
| Active | 4 yrs |
| Locations | 1 |
Strong profile, led by profitability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Fiscal year | 2023 |
|---|---|
| Revenue | - |
| EBITDA | €-12k |
| Net profit | €-15k |
| Cash flow | €-12k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €29k |
| Equity | €-40k |
| Debt | €70k |
| of which ≤ 1y | €70k |
| of which > 1y | - |
| Working capital | €-57k |
| Employees (FTE) | - |
| 2023 | |
|---|---|
| Current ratio | 0.17 |
| Quick ratio | 0.17 |
| Working capital ratio | -195.2% |
| Solvency | -136.3% |
| Debt / equity | -1.73 |
| Long-term debt ratio | - |
| Interest coverage | -143.81 |
| Gross margin | - |
| Net margin | - |
| ROA | -49.4% |
| ROE | 36.2% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €29k |
| Fixed assets | 21/28 | €17k |
| Intangible fixed assets | 21 | €16k |
| Financial fixed assets | 28 | €900 |
| Current assets | 29/58 | €12k |
| Amounts receivable within one year | 40/41 | €10k |
| Cash & bank | 54/58 | €2k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €29k |
| Equity | 10/15 | €-40k |
| Contributions / capital | 10/11 | €5k |
| Accumulated profits (losses) | 14 | €-45k |
| Amounts payable | 17/49 | €70k |
| Amounts payable within one year | 42/48 | €70k |
| Trade debts payable within one year | 44 | €12k |
| Income statement | ||
| Gross operating margin | 9900 | €-9k |
| Operating result | 9901 | €-14k |
| Financial charges | 65 | €81 |
| Result before taxes | 9903 | €-15k |
| Net result for the period | 9904 | €-15k |
| Result to be appropriated | 9905 | €-15k |
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 15-07-2021 |
| Status | Active |
| Postal code | 1050 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21447B0298/00W013 | Brussels | 1,244 m² | 1 · 389 m² | 19.6 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
03-01-2024 Transaction in capital or shares
Technical details
{
"events": [],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Ixelles",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": null,
"filing_date": "2023-12-21",
"act_kind_objet": "Objet(s) de l\u0027acte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": null,
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": "2023-09-29"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0771.461.685",
"name_full": "PharmaDEXI",
"legal_form": "SOCIETE A RESPONSABILITE LIMITEE",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"shareholders_after": [],
"share_classes_after": []
}26-01-2023 Capital increase of €12,500 to €52,500
- €40.000 → €52.500
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 52500.0,
"delta_eur": 12500.0,
"before_eur": 40000.0,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Andry RABEMANANTSOA",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 100,
"contribution_amount_eur": 12500.0
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Mohamed BOURIA",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 100,
"contribution_amount_eur": 12500.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": 100,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 125.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 12500.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
}
],
"notary": {
"name": "Damien COLLON-WINDELINCKX",
"firm_city": null,
"firm_name": "Damien COLLON, Notaire SRL",
"office_city": "Etterbeek",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2023-01-26",
"filing_date": "2023-01-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2023-01-23",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": "2023-01-23"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0771.461.685",
"name_full": "PharmaDEXI",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Michaelina de Radzitzky",
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"pacte d\u2019actionnaires"
],
"shareholders_after": [
{
"kbo": null,
"pct": 19.047619047619047,
"kind": "person",
"name": "Andry RABEMANANTSOA",
"role": "aandeelhouder",
"n_shares": 100,
"share_class": null
},
{
"kbo": null,
"pct": 19.047619047619047,
"kind": "person",
"name": "Mohamed BOURIA",
"role": "aandeelhouder",
"n_shares": 100,
"share_class": null
}
],
"share_classes_after": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PharmaDEXI |